Leap Therapeutics (Nasdaq:LPTX) - Hisse Senedi Fiyatı, Haberler ve Analizler

LPTX Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Leap Therapeutics, Inc. kanser tedavisi için antikor tedavileri satın almakta ve geliştirmektedir. Daha fazla detay

LPTX temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Anlamlı bir piyasa değeri yok ( $99M )

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Leap Therapeutics, Inc. Rakipler

I-Mab

NasdaqGM:IMAB

US$79.8m

SELLAS Life Sciences Group

NasdaqCM:SLS

US$79.8m

Kyverna Therapeutics

NasdaqGS:KYTX

US$177.9m

Immuneering

NasdaqGM:IMRX

US$60.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Leap Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.58
52 Haftanın En Yüksek Seviyesi	US$5.00
52 Haftanın En Düşük Seviyesi	US$1.68
Beta	0.22
11 Aylık Değişim	-15.13%
3 Aylık Değişim	-5.15%
1 Yıllık Değişim	-9.79%
33 Yıllık Değişim	-88.88%
5 Yıllık Değişim	-62.11%
Halka arzdan bu yana değişim	-96.72%

Son Haberler & Güncellemeler

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18

Hissedar Getirileri

	LPTX	US Biotechs	US Pazar
7D	-10.7%	-3.7%	0.3%
1Y	-9.8%	15.2%	31.1%

Getiri vs. Endüstri: LPTX geçen yıl % 15.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: LPTX geçen yıl % 31.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is LPTX's price volatile compared to industry and market?
LPTX volatility
LPTX Average Weekly Movement	11.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: LPTX hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: LPTX 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2011	54	Doug Onsi	www.leaptx.com

Bir biyofarmasötik şirketi olan Leap Therapeutics, Inc. kanser tedavisi için antikor tedavileri satın almakta ve geliştirmektedir. Öncü ürün adayları arasında, özofagogastrik ve jinekolojik kanserlerin tedavisi için devam eden çok sayıda klinik çalışmada bulunan Dickkopf ile ilişkili protein 1'i inhibe eden monoklonal bir antikor olan DKN-01; ve hücre yüzeylerinde Claudin18.2 eksprese eden hücreleri hedef alan ve faz II klinik çalışmada bulunan monoklonal bir antikor olan FL-301'in yanı sıra FL-302 ve FL-501 olmak üzere iki preklinik antikor programı bulunmaktadır. Leap Therapeutics, Inc. şirketinin NovaRock, Adimab ve BeiGene, Ltd.

Leap Therapeutics, Inc. Temel Bilgiler Özeti

Leap Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LPTX temel i̇stati̇sti̇kler
Piyasa değeri	US$99.10m
Kazançlar(TTM)	-US$64.82m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.5x

F/K Oranı

LPTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LPTX gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$64.82m
Kazançlar	-US$64.82m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.69
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

LPTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LPTX Stoklara Genel Bakış

Risk Analizi

Leap Therapeutics, Inc. Rakipler

NasdaqGM:IMAB

US$79.8m

NasdaqCM:SLS

US$79.8m

NasdaqGS:KYTX

US$177.9m

NasdaqGM:IMRX

US$60.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Price target decreased by 10.0% to US$2.70

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Price target decreased to US$3.60

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

First half 2022 earnings released

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Price target decreased to US$4.40

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Consensus forecasts updated

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

Consensus revenue estimates increase by 99%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Leap Therapeutics: Waiting For One More Leap

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Insufficient new directors

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics: All On The Line

Price target increased to US$4.50

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

Price target decreased to US$4.00

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue and earnings miss expectations

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

New 90-day high: US$2.63

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

New 90-day high: US$2.42

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

New 90-day high: US$2.37

Analysts update estimates

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)